Browse CCR2

Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=The chemoattractant receptors are distributed throughout the cell surface; after stimulation with a ligand, such as CCL2, they are rapidly recruited into microdomain clusters at the cell membrane.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for the CCL2, CCL7 and CCL13 chemokines (PubMed:23408426). Receptor for the beta-defensin DEFB106A/DEFB106B (PubMed:23938203). Transduces a signal by increasing intracellular calcium ion levels (By similarity). Upon CCL2 ligation, mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable). ; FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001819 positive regulation of cytokine production
GO:0001974 blood vessel remodeling
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002278 eosinophil activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002407 dendritic cell chemotaxis
GO:0002434 immune complex clearance
GO:0002436 immune complex clearance by monocytes and macrophages
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002447 eosinophil mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002548 monocyte chemotaxis
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002691 regulation of cellular extravasation
GO:0002693 positive regulation of cellular extravasation
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002827 positive regulation of T-helper 1 type immune response
GO:0002828 regulation of type 2 immune response
GO:0002829 negative regulation of type 2 immune response
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002887 negative regulation of myeloid leukocyte mediated immunity
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006887 exocytosis
GO:0006968 cellular defense response
GO:0007159 leukocyte cell-cell adhesion
GO:0007194 negative regulation of adenylate cyclase activity
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007259 JAK-STAT cascade
GO:0008347 glial cell migration
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010720 positive regulation of cell development
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010820 positive regulation of T cell chemotaxis
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0016525 negative regulation of angiogenesis
GO:0017157 regulation of exocytosis
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031280 negative regulation of cyclase activity
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032609 interferon-gamma production
GO:0032623 interleukin-2 production
GO:0032640 tumor necrosis factor production
GO:0032649 regulation of interferon-gamma production
GO:0032663 regulation of interleukin-2 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032729 positive regulation of interferon-gamma production
GO:0032743 positive regulation of interleukin-2 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0035696 monocyte extravasation
GO:0035697 CD8-positive, alpha-beta T cell extravasation
GO:0035700 astrocyte chemotaxis
GO:0035701 hematopoietic stem cell migration
GO:0035704 helper T cell chemotaxis
GO:0035705 T-helper 17 cell chemotaxis
GO:0036230 granulocyte activation
GO:0036336 dendritic cell migration
GO:0040017 positive regulation of locomotion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042063 gliogenesis
GO:0042088 T-helper 1 type immune response
GO:0042089 cytokine biosynthetic process
GO:0042092 type 2 immune response
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042535 positive regulation of tumor necrosis factor biosynthetic process
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043301 negative regulation of leukocyte degranulation
GO:0043307 eosinophil activation
GO:0043308 eosinophil degranulation
GO:0043309 regulation of eosinophil degranulation
GO:0043310 negative regulation of eosinophil degranulation
GO:0043615 astrocyte cell migration
GO:0045055 regulated exocytosis
GO:0045123 cellular extravasation
GO:0045761 regulation of adenylate cyclase activity
GO:0045765 regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0045920 negative regulation of exocytosis
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046631 alpha-beta T cell activation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0048247 lymphocyte chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0048771 tissue remodeling
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050777 negative regulation of immune response
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051339 regulation of lyase activity
GO:0051350 negative regulation of lyase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051962 positive regulation of nervous system development
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0060627 regulation of vesicle-mediated transport
GO:0070098 chemokine-mediated signaling pathway
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072522 purine-containing compound biosynthetic process
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0072683 T cell extravasation
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090264 regulation of immune complex clearance by monocytes and macrophages
GO:0090265 positive regulation of immune complex clearance by monocytes and macrophages
GO:0097529 myeloid leukocyte migration
GO:0097696 STAT cascade
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901623 regulation of lymphocyte chemotaxis
GO:1902566 regulation of eosinophil activation
GO:1902567 negative regulation of eosinophil activation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903531 negative regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903975 regulation of glial cell migration
GO:1903977 positive regulation of glial cell migration
GO:2000147 positive regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
GO:2000407 regulation of T cell extravasation
GO:2000409 positive regulation of T cell extravasation
GO:2000437 regulation of monocyte extravasation
GO:2000439 positive regulation of monocyte extravasation
GO:2000449 regulation of CD8-positive, alpha-beta T cell extravasation
GO:2000451 positive regulation of CD8-positive, alpha-beta T cell extravasation
GO:2000458 regulation of astrocyte chemotaxis
GO:2000464 positive regulation of astrocyte chemotaxis
GO:2000471 regulation of hematopoietic stem cell migration
GO:2000473 positive regulation of hematopoietic stem cell migration
Molecular Function GO:0001637 G-protein coupled chemoattractant receptor activity
GO:0001653 peptide receptor activity
GO:0001664 G-protein coupled receptor binding
GO:0004896 cytokine receptor activity
GO:0004950 chemokine receptor activity
GO:0005126 cytokine receptor binding
GO:0008528 G-protein coupled peptide receptor activity
GO:0016493 C-C chemokine receptor activity
GO:0031727 CCR2 chemokine receptor binding
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
Cellular Component GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome R-HSA-6803157: Antimicrobial peptides
R-HSA-1461957: Beta defensins
R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1461973: Defensins
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26056232Breast CarcinomaInhibit immunityPulmonary metastasis of breast cancer cells is promoted by a distinct population of macrophages, metastasis-associated macrophages (MAMs), which originate from inflammatory monocytes (IMs) recruited by the CC-chemokine ligand 2 (CCL2). We demonstrate here that, through activation of the CCL2 receptor CCR2, the recruited MAMs secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice.
29036438Gastric CarcinomaInhibit immunity (T cell function)We generated a xenograft mouse model and used SEW-2871, a S1P1 specific agonist to activate S1P1 signalling. SEW-2871 promoted tumor growth in our mouse model, and induced a higher level of MDSC and a reduced level of CD8+CD69+ T cells within tumor. Additionally, SEW-2871 enhanced expression of several MDSC recruitment-associated chemokines (CXCL12, CXCL5 and CCL2) in tumor cells. These chemokines facilitated MDSC migration by interaction with CCR2, CXCR2 and CXCR4. S1P1 signalling promoted gastric cancer by enhancing chemokine expression in tumor cells and recruiting MDSC to tumor microenvironment, which impaired anti-tumoral function of TILs.
23686489B16 Malignant MelanomaPromote immunity (T cell function)We show that the inflammatory chemokine CCL2 and its receptor CCR2 are necessary for the accumulation of γδ TILs in B16 lesions, where they produce IFN-γ and display potent cytotoxic functions. Strikingly, the lack of γδ TILs in TCRδ-deficient but also in CCR2-deficient mice enhanced tumor growth in vivo, thus revealing an unanticipated protective role for CCR2/CCL2 through the recruitment of γδ T cells.
27680685Breast cancinoma; Oral Squamous Cell CarcinomaInhibit immunity (T cell function)The CCL2 chemokine receptor CCR2 drives cancer by mediating the recruitment of monocytes and myeloid-derived suppressor cells to the tumor microenvironment. Following tumor initiation, an expanded population of CCR2+ Tregs required CCR2 expression to traffic between draining lymph nodes (dLN) and the tumor. Notably, in mouse models, low-dose cyclophosphamide treatment preferentially depleted CCR2+ Treg, enhancing priming of tumor-specific CD8+ T cells. In the MMTV-PyMT transgenic mouse model of breast cancer and in oral squamous cell carcinoma patients, tumor development was associated with decreased blood frequency and inversely increased tumor frequency of CCR2+ Tregs. Our results define a novel subset of CCR2+ Treg involved in tumoral immune escape.
23221383pancreatic carcinomaInhibit immunityTargeting CCR2 or CSF1R improves chemotherapeutic efficacy, inhibits metastasis, and increases antitumor T-cell responses.
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Sensitive to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1950.667
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0060.995
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3340.625
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2250.716
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4790.713
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0920.951
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6890.291
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1770.311
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2440.838
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7730.532
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0330.986
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1120.637
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCR2
Namechemokine (C-C motif) receptor 2
Aliases CC-CKR-2; CKR2; MCP-1-R; CD192; FLJ78302; CMKBR2; CCR-2A; CCR2B; CKR2A; CKR2B; MCP-1 receptor; monocyte chem ......
Chromosomal Location3p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCR2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCR2.
ID Name Drug Type Targets #Targets
DB05130INCB3284Small MoleculeCCR21
DB05159CCX915Small MoleculeCCR21
DB12520PlozalizumabBiotechCCR21